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perspectives
Dick AW Janssen1 
Frank MJ Martens1 
Liesbeth L de Wall1 
Hendrikje MK van Breda2 
John PFA Heesakkers1
1Department of Urology, Radboud 
University Nijmegen Medical Center, 
Nijmegen, 2Department of Urology, 
University Medical Center Utrecht, 
Utrecht, the Netherlands
Objectives: This review describes the evidence from established and experimental therapies 
that use electrical nerve stimulation to treat lower urinary tract dysfunction.
Methods: Clinical studies on established treatments such as percutaneous posterior tibial 
nerve stimulation (P-PTNS), transcutaneous electrical nerve stimulation (TENS), sacral nerve 
stimulation (SNS) and sacral anterior root stimulation (SARS) are evaluated. In addition, 
clinical evidence from experimental therapies such as dorsal genital nerve (DGN) stimulation, 
pudendal nerve stimulation, magnetic nerve stimulation and ankle implants for tibial nerve 
stimulation are evaluated.
Results: SNS and P-PTNS have been investigated with high-quality studies that have shown 
proven efficacy for the treatment for overactive bladder (OAB). SARS has proven evidence-
based efficacy in spinal cord patients and increases the quality of life. TENS seems inferior to 
other OAB treatments such as SNS and P-PTNS but is noninvasive and applicable for ambulant 
therapy. Results from studies on experimental therapies such as pudendal nerve stimulation 
seem promising but need larger study cohorts to prove efficacy.
Conclusion: Neurostimulation therapies have proven efficacy for bladder dysfunction in patients 
who are refractory to other therapies.
Significance: Refinement of neurostimulation therapies is possible. The aim should be to 
make the treatments less invasive, more durable and more effective for the treatment of lower 
urinary tract dysfunction.
Keywords: neuromodulation, overactive bladder syndrome, sacral nerve stimulation, sacral 
anterior root stimulation, PTNS, implant
Introduction
The urinary bladder is a low-pressure storage reservoir for urine. Neurological control 
of the bladder, urethra and pelvic floor muscles is complex and depends on differ-
ent peripheral, spinal and central nerves and multiple reflex pathways.1 Learning to 
adequately control the bladder reflexes is a difficult task in human development and 
takes an average of 5 years.2,3 The lower urinary tract is sensitive for disturbances. 
Overactive bladder (OAB) is a complex of storage symptoms that includes urgency with 
or without urinary incontinence, frequency and nocturia. Idiopathic OAB (iOAB), the 
most common form, has an unresolved etiology, but aging is an important risk factor.4 
The following four factors are believed to play a role in OAB etiology: 1) enhanced 
afferent nerve activation, 2) increased efferent excitation, 3) decreased inhibition by 
the central nervous system (CNS) and 4) phasic smooth muscle contractions.4
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Bladder control can also be one of the first mechanisms 
to fail in neurodegenerative diseases.5 There are many 
neurological disorders that can result in lower urinary tract 
dysfunction. Some examples of these are multiple sclerosis, 
Parkinson’s disease and spinal cord injury (SCI). In the 
bladder, this often causes OAB. Contrastingly, this can also 
cause detrusor hypocontractility and the inability to void 
adequately, which is frequently seen in cauda syndrome and 
spina bifida patients. Finally, neurologic disturbances can 
cause obstructive voiding due to detrusor external sphincter 
dyssynergia (DESD), which is a flawed coordination between 
bladder and external urethral sphincter (EUS).3 A combina-
tion between severe detrusor overactivity (DO) and DESD 
can cause renal reflux and insufficient drainage of the upper 
urinary tract. This results in high pressures that can cause 
kidney damage.
Lower urinary tract dysfunction has a profound negative 
impact on the quality of life.6 For decades now, urologists 
have designed and implemented neurostimulation therapies 
to treat lower urinary tract dysfunction with success. Many 
of these different therapies have an unique approach and 
are clinically applied worldwide (Figure 1). This review 
outlines the current knowledge on neurologic control and 
dysfunction of the lower urinary tract and describes how 
the different neurostimulation therapies intervene in these 
processes. Clinical evidence is reviewed to highlight the 
advantages and disadvantages of different neurostimula-
tion techniques.
Figure 1 Summary of therapeutic options (clinical and experimental) for electrical nerve stimulation for lower urinary tract dysfunction.
Notes: (A) Different sites where electrical nerve stimulation is applied for the treatment of lower urinary tract dysfunction. (B) An X-ray image (AP) of the right ankle area 
of a patient who has an Urgent-SQ™ implantable device for on demand posterior tibial nerve stimulation. The yellow arrow depicts the wire electrode fixation near the 
posterior tibial nerve. (C) An X-ray image (lateral) of a right ankle of a patient with a BlueWind implantable device for on demand posterior tibial nerve stimulation. The 
electrodes are positioned on the upper and lower sides of the device (green arrows). (D) An X-ray (AP) of the pelvic area from a patient undergoing the PNE test phase for 
evaluation if SNS is effective. The green arrow is the percutaneously placed wire electrode that is inserted through the left S3 foramen. If effective, the patient will receive a 
permanent tined lead electrode and in a later phase an InterStim implant.
Abbreviations: AP, anterior posterior view; CNS, central nervous system; DGN, dorsal genital nerve; PNE, percutaneous nerve evaluation; SNS, sacral nerve stimulation; 
PMC, pontine micturition center.
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Lower urinary tract control
The lower urinary tract is semiautonomous. This means that 
one cannot influence the force of a bladder contraction, but it 
is possible, to a large degree, to suppress bladder contractions 
during the storage phase, initiate voiding and to consciously 
control the EUS. For successful storage and voiding, there has 
to be a finely tuned coordination between the detrusor smooth 
muscles and the bladder outlet, which consist of the bladder 
neck (internal sphincter) and EUS. Besides this, there also has 
to be adequate sensory signaling to monitor bladder filling. 
The efferent and afferent pathways that control micturition 
are organized with at least three different peripheral nerves 
that innervate the bladder and sphincters, which include the 
parasympathic, sympathic and somatic nerves, and each will 
be described in detail in the following paragraphs.
Bladder detrusor contraction is controlled by the para-
sympathic sacral nerves (pelvic nerve) that originate from 
the S2-S4 region in the spinal cord1,7 (Figure 2). The sacral 
nerves hold besides efferent fibers, many afferent fibers that 
convey bladder-filling sensations. The sacral nerves use 
the neurotransmitter acetylcholine (ACh) and muscarinic 
receptors (mostly M3, also M2) for signaling. These mus-
carinic receptors are the main pharmacological target sites 
to treat OAB (Figure 2). Examples of this are widespread 
use of antimuscarinics and intradetrusor botulinum toxin 
A injections that are both evidence-based therapies that 
are included in all major therapy guidelines for neurogenic 
OAB and iOAB.8–10
The urethra is predominantly innervated by the pudendal 
nerve that originates from S2–S4 in the spinal cord (Figure 2). 
From there, the branches go through the Alcock’s canal into 
the areas deep in the pelvis. This somatic nerve uses ACh and 
nicotine receptors for signaling. The nerve is mostly known 
for its motor control of the EUS, but it also innervates the 
external rectal sphincter, the scrotal muscles and the perineal 
area. There is also a branch called the dorsal genital nerve 
(DGN) that innervates the penis or clitoris and is important 
for sexual function (Figure 1). Besides efferent nerves, the 
pudendal nerve has many afferent fibers that sense urine flow 
through the urethra.1
The EUS is essential for normal urinary tract function 
and it is under voluntary control, which means that a person 
can decide to contract and relax the striated muscle fibers of 
their sphincter and to interrupt voiding. These motor nerves 
originate in a specific area in the ventral horns of the sacral 
spinal cord called Onuf’s nucleus.1,3
Inhibition of voiding is done with a third peripheral 
nerve called the hypogastric nerve that originates from the 
T11-L2 region in the spinal cord (Figure 2). The branches 
of this sympathic nerve innervate the bladder dome and 
Figure 2 Pelvic nerve anatomy and lower urinary tract neural control.
Notes: (A) A model of the different nerves that innervate and control the lower urinary tract. (B) Pelvic nerve anatomy.
Abbreviations: CNS, central nervous system; PMC, pontine micturition center.
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bladder neck and use predominantly norepinephrine (nor-
adrenalin) as a neurotransmitter. In the bladder dome, it 
activates β3-receptors that inhibit detrusor contractions 
(thereby inhibiting cholinergic activation). In the bladder 
neck, it does the opposite and activates α1-receptors that 
contract the striated muscles of the internal sphincter. Both 
β3- and α1-receptors are used for pharmacological therapy 
(Figure 2). β3-agonists relax the detrusor, and α1-receptor 
antagonists are used to relax the proximal urethra (bladder 
neck) in outflow obstruction patients.
The central neural control for storage and voiding is 
located in the brain stem, where lies the periaqueductal gray 
(PAG) and pontine micturition center (PMC). The PMC is 
inactive in the storage phase during which the bladder sacral 
efferents are inhibited, resulting a relaxed detrusor, combined 
with a contraction of the bladder neck and EUS.11 The PAG 
receives afferent information from the lower urinary tract and 
further communicates with the higher brain centers including 
the forebrain. The PAG is the site that the central nervous 
system targets to initiate voiding (Figure 2). When afferent 
signals in the PAG reach a certain threshold and there is 
permission to void (implying no inhibition from higher brain 
centers), it activates the PMC to initiate voiding reflexes.
During storage and voiding, bladder and sphincter 
coordination is based on reflex mechanisms.1,3 Two normal 
reflexes are active in the storage phase. The storage reflex 
includes the hypogastric nerve to initiate smooth muscle fiber 
contraction in the bladder neck and inhibits detrusor smooth 
muscle activation by the sacral efferent nerves. The second 
reflex is the guarding reflex. This sacral reflex increases 
sphincter tonus during sudden abdominal pressure increases 
to maintain continence.12 The spinobulbospinal or somatic 
micturition reflex is a voiding reflex. This reflex is activated 
at start of a void and is maintained throughout voiding and 
works by 1) inhibiting the guarding reflex, 2) coordinating 
the voiding contraction of the detrusor and 3) relaxing the 
bladder outlet.11 The spinobulbospinal reflex is triggered 
by afferent firing due to flow in the urethra and the voiding 
contraction of the bladder. The PMC plays the central role 
in initiating and maintaining this reflex. Besides these nor-
mal reflexes, neurologic disease or inflammation can cause 
pathologic or noxious reflexes that decrease the inhibitory 
control of the bladder.
The synchronization of the nerves that controls the lower 
urinary tract is mediated through different peripherally and 
centrally located ganglion cells.1 The sacral nerves innervate 
the bladder wall through the pelvis and form a large part of 
the pelvic plexus. The pelvic plexus contains different auto-
nomic ganglia that signal between ganglia in 1) the bladder 
wall (intramural), 2) the pelvis, 3) the posterior (dorsal) and 
anterior roots, 4) the spinal cord and 5) the brain. Connecting 
the afferent and the efferent systems is done with interneu-
rons in the spinal cord. These interneurons relay afferent and 
efferent signals to and from the brain, but there are also inter-
neurons that have inhibitory or excitatory synapses between 
afferent and efferent neurons within the spinal cord.1 Besides 
the sacral nerves, the pelvis also contains other nerves that 
innervate the EUS, rectum, uterus, genitals and nerves that 
descend toward the lower extremities. There are three pro-
posed pathways for cross talk between visceral pelvic organs 
and cross-sensitization.13 The first pathway is the interaction 
at the spinal cord level. The nerves in the pelvis use many 
communal sensory and motor roots of which many lie in the 
sacral spinal cord.14 For instance, afferent fibers form sacral 
and pudendal nerves that enter the dorsal horns of the sacral 
spinal cord at a similar level.1 The second proposed pathway 
can be described as descending modulation by higher brain 
centers.15,16 This pathway describes how higher brain centers 
can modulate spinal nociceptive processing, which occurs 
after exposure to visceral pain for long periods of time or 
during period of chronic stress.15 The third pathway is cross 
talk through peripheral sensitization. There are multiple 
animal studies that show that afferent pain signals from one 
organ can induce a neuroinflammatory response in another 
pelvic organ.17,18 Studies by Pezzone et al19 and Winnard et al17 
show that this could be possible because some DRG neurons 
have multiple axons or dichotomizing axons that innervate 
different pelvic organs. This cross talk between pelvic organs 
gives an explanation for the correlation between bladder pain 
and other somatic disorders that are part of chronic pelvic 
pain such as irritable bowel syndrome.
Neuromodulation
Continuous or intermittent electrical nerve stimulation 
strategies are used to treat lower urinary tract dysfunction. 
Neuromodulation is used to treat both DO and detrusor 
underactivity, but it is also currently used to treat bladder 
pain. Electrical stimulation is performed at different sites 
of the human body and therefore targets different nerves 
( Figure 1). Some of these target nerves are directly involved 
in lower urinary tract sensory-motor control, such as the 
sacral or pudendal nerves, while others are more indirectly 
involved, such as the DGN and the posterior tibial nerve 
(PTN). The PTN is a distal branch of the sciatic nerve that 
originates in the pelvis (L5-S3 spinal roots) and descends 
toward the lower extremities (Figures 1 and 2). Stimulating 
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the PTN has an effect on lower urinary tract function. Chi-
nese acupuncturists have been applying stimulation in the 
area of the PTN to treat lower urinary tract dysfunction for 
centuries. Nowadays, electrical stimulation of the PTN is an 
established therapy to treat lower urinary tract dysfunction 
with proven clinical efficacy.20,21
Much of what is known about the biologic effects of elec-
trical stimulation therapies for lower urinary tract dysfunc-
tion comes from animal studies that investigated how neural 
stimulation interacts on the different peripheral, spinal and 
higher CNS pathways. Most of these studies show that elec-
trical stimulation of the sacral nerve roots or the peripheral 
nerves will not inhibit the primary efferent nerves directly 
but operate by modulating afferent nerve signaling.22–24 Zhang 
et al demonstrated in a feline model that it was the direct 
stimulation of the S1–S3 dorsal roots and not the ventral roots 
that inhibit bladder contractions.22 A similar effect is seen 
when SCI patients with severe DO undergo a dissection of 
the dorsal (sensory) roots (rhizotomy) to successfully inhibit 
DO.25 This suggests that electrical stimulation has an indirect 
effect that modulates interneural transmission pathways.22 
The effect of electrical stimulation in different locations 
such as the sacral, pudendal or tibial area could therefore 
result in modulation of different pathways or have a differ-
ent effect on a single pathway. The study from Xiao et al24 
provides interesting clues for this. They performed pudendal 
nerve stimulation and tibial nerve stimulation in felines with 
transected sacral spinal cords and demonstrated that pudendal 
nerve stimulation was still successful in inhibiting bladder 
contraction amplitudes, but tibial nerve stimulation was not. 
This implies that for lower urinary tract function, pudendal 
nerve stimulation acts on lower sacral reflex pathways, and 
tibial nerve stimulation modulates another pathway that 
includes suprasacral spinal cord regions such as the brain.
Other evidence for central nervous effects of neuro-
modulation in humans comes from functional magnetic 
resonance imaging studies.26,27 Kavia et al27 demonstrated in 
Fowler syndrome patients that these subjects had an overall 
low activity in the brain areas that process bladder afferent 
signals such as the PAG, but these regions could however 
be reactivated with sacral neuromodulation. Blok et al26 
showed that continuous electrical nerve stimulation in the 
sacral area with sacral nerve stimulation (SNS) modulates 
the brain regions that are associated with learning behavior. 
These include areas that are associated with detrusor hyper-
activity and areas for alertness and awareness. This implies 
that neuromodulation gives patients more control over their 
bladder. The clinically applied neurostimulation techniques 
and the current evidence for these therapies will be explained 
in the next section.
Sacral anterior root stimulation (SARS)
SARS was already developed in the sixties by Brindley and 
clinically applied in SCI patients in the early eighties.25,28,29 
Electrical currents are used to activate sacral anterior 
(motor) roots of S2, S3 and S4 spinal cord segments to 
accomplish, respectively, voiding, defecation and erections 
in complete SCI patients who have lost all these functions. 
The device itself is nowadays called the Finetech-Brindley 
System (Finetech Medical Ltd., Welwyn Garden City, 
UK). It requires 1) surgically implanted electrodes that are 
attached to the anterior roots, 2) an internal receiver and 3) 
an external controller with a transmitter block (Figure 3). 
The initial surgery for the placement of the electrodes can 
be performed intradural and extradural in both open and 
laparoscopic procedures. An essential step of the surgical 
procedure is the isolation of the dorsal (sensory) and ante-
rior (motor) roots of spinal cord segments S2, S3 and S4. 
The intradural procedure requires a sacral laminectomy to 
accomplish this. After this, the spinal cord roots are stimu-
lated individually with electrical currents to investigate their 
function. Dorsal sensory roots form a reflex arch with the 
anterior motor roots, and this influences motor control over 
the bladder. Leaving the dorsal roots intact therefore leads 
to persistent DO. Therefore, a rhizotomy is done to surgi-
cally dissect the dorsal (sensory) roots. Despite the benefits 
of preventing bladder reflex activity and hardly any side 
effects in patients with complete spinal cord lesions, the 
patients are sometimes reluctant to undergo this necessary 
surgical procedure. Martens et al30 evaluated reasons for this, 
and patients reported the irreversible damage to the dorsal 
roots caused by the procedure as one of the main motives 
for not undergoing the procedure. After the rhizotomy, the 
designated anterior roots are organized and fixated in an 
electrode book that contains the electrodes to stimulate the 
different motor roots separately (Figure 3). From there, the 
electrical wires are tunneled to a subdermal receiver on the 
abdominal side. Patients have to be able to localize this 
area easily. The internal receiver has a pulse generator and 
is activated by a radiofrequency transmitted signal from 
an external transmitter block. This is done by placing the 
external transmitter block on the skin overlapping the site 
of the internal receiver. The remote control to which the 
external transmitter block is connected has settings for dif-
ferent programs that can be altered for voiding, defecation 
and erection function. Individual fine tuning of the programs 
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is possible with alterations in the pulse frequency, intensity 
and duration for each of the three anterior roots. Voiding is 
however different compared to the normal situation. Electri-
cal stimulation of sacral anterior roots contracts the smooth 
muscle fibers of the detrusor and also the striated muscles of 
the bladder neck and urethral external sphincter. Continuous 
stimulation would therefore result in a dyssynergia between 
bladder and sphincter coordination during voiding. This 
problem is overcome by burst stimulation. After each burst, 
there is a fast relaxation of the striated sphincter muscles, but 
a much slower relaxation of the detrusor smooth muscles, 
resulting in bladder emptying between the stimulation bursts. 
This gives an intermittent voiding pattern that is called 
poststimulus voiding.
The Finetech–Brindley System can significantly improve 
the quality of life and independence of spinal cord patients.29,30 
Getting control over the lower urinary tract with this device 
can reduce or abolish the need for bladder catherization 
and reduce the number of urine tract infections.29,30 But the 
device can also decrease constipation problems and restore 
some of the erectile function in patients.29,30 Incontinence, for 
example, is improved with 50% of patients who are fully con-
tinent with the device compared to 13% of a control group.30 
Martens also evaluated quality-of-life aspects in this study 
with a cohort of 46 patients with a Finetech–Brindley System 
and 28 SCI controls. The study showed that the patients with 
SARS have a significantly better feeling of general health and 
social functioning and also less limitations, anxiety and bad 
feeling concerning their urinary problems.30
It is, however, important to address and manage patient’s 
expectations. The initial surgery is a lengthy procedure and 
can cause anterior root damage and cerebrospinal fluid leak-
age.25,28 Surgery is also not always successful for all three 
functions. For instance, Brindley and Rushton29 reported 
that after 5–11 years, only one-third of male patients get 
implant driven erections. The Martens et al30 study showed 
poorer outcomes and reported successful erectile function 
in only 0%–32% of patients. Apart from this, the patients 
have to be consulted that the therapy does not bring back 
genital sensations.30
Figure 3 SARS therapy for spinal cord injury patients.
Notes: (A) How anterior roots S2, S3 and S4 are connected to electrodes in an electrode book. The electrodes are guided to an internal receiver (called a Chimney 
procedure). The receiver can be activated with an external controller. The two “X” depict a laminectomy to gain access to the nerves (for the intradural procedure) and a 
rhizotomy of the dorsal horn of S2–S4. (B) An X-ray image (AP) of the upper pelvic area of a patient with a Finetech–Brindley System. The yellow arrow depicts the electrode 
book where the electrodes are connected to the anterior roots of S2, S3 and S4. The wire electrodes are guided to the internal electrical pulse receiver plate that is shown 
as the green triangle.
Abbreviations: AP, anterior posterior view; SARS, sacral anterior root stimulation.
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The average life span of the technical equipment is 
reasonably good. The device is quite robust and does not 
use any internal battery. Brindley and Rushton29 showed in 
a long-term follow up study (5–11 years) in 50 patients that 
41 patients were still using their device for voiding and 27 
for defecation. Martens et al30 however showed lower scores 
in a group of over 70 patients (63% still using the device). 
Technical failure therefore does happen and restoration 
requires renewed surgery in a group of patients who have an 
increased health risk.29,30 A factor that also has to be taken 
into account is that program settings sometimes need to be 
adjusted over time. This can be caused by either technical 
problems with the system or possibly the slow changes in 
lower urinary tract function in SCI patients. Overall, patient 
satisfaction with SARS is high and is currently the only 
option for complete SCI patients to regain neurologic control 
over their lower urinary tract.30
SNS
SNS is a neurostimulation technique that has evidence-based 
clinical applicability. SNS aims to restore bladder neural con-
trol for both OAB and urinary retention.8,31,32 The technique 
was developed by Tanagho and Schmidt in the late eighties 
for neurogenic bladder disease. In Europe, the device was 
implanted for the first time in 1989 by van Kerrebroeck 
(Figure 4). Later on, this technique was investigated for the 
treatment of fecal incontinence for which it was also FDA 
approved in the nineties. The SNS technique involves the 
placement of an implantable electrode through the sacral 
foramen of typically S3 to stimulate the sacral and pudendal 
nerves (Figure 4). The electrode is tunneled subcutaneously 
and connected to a surgically placed internal pulse generator 
(Figure 4). The InterStim device (Medtronic, Minneapolis, 
MN, USA) is currently the only device that is clinically used, 
and according to the manufacturer, over 1,750,000 devices 
have currently been implanted.
When SNS was developed, the initial thought was that 
targeting the pudendal nerve with electrical stimulation 
would help contract the EUS and pelvic floor. However, uro-
dynamic studies showed that SNS was actually very potent 
in inhibiting DO. Like stated before, the main hypothesis 
now is that SNS inhibits DO not by direct inhibition of the 
efferent motor nerves to the detrusor but by modulating 
the lower urinary tract reflexes via the afferent nerves and 
interneurons in the spinal cord.14,33,34 Electrical stimulation 
of the afferents from the bladder and sphincter is thought to 
correct the unbalanced neural signaling that causes the lower 
urinary dysfunction. This latter hypothesis also explains why 
SNS can inhibit DO and activate the detrusor in patients 
with urinary retention.
Before patients undergo a surgical implantation of the 
InterStim device, a testing phase is performed to evaluate 
whether the therapy is successful. This test phase is called the 
percutaneous nerve evaluation (PNE). During the PNE pro-
cedure, a hollow needle electrode is transcutaneous inserted 
through the different sacral foramina of S2, S3 and S4 in a 
conscious patient. Positioning and stimulation of the needle 
is done to evaluate 1) the sensations of the patient that are 
ideally described as nondisturbing tingly sensations in genital 
or perineal areas and 2) motor reflexes such as the bellows 
reflex (levator ani contraction visible in perineal area) and 
flexing of the big toe (PTN reflex). After choosing the optimal 
position, the needle will be replaced by 1) a tined electrode 
(e.g., tined lead) with four stimulation points (Figure 4) or 
2) a wire electrode with one stimulation point (Figure 1). 
These electrodes will be connected to an external stimulator 
device that generates continuous electrical pulses that can 
be adjusted in intensity and frequency. Testing can be done 
with one electrode or with two bilaterally placed electrodes.35 
The Pham study reported significantly higher success rates 
of the PNE test in patients who were evaluated with bilateral 
electrodes, but these results were not supported by an earlier 
study by Scheepens et al.36,37 After the procedure, the patients 
are evaluated to objectify how much improvement is in their 
symptoms with SNS. This is done with voiding diaries and 
urodynamic investigations (especially in patients with urinary 
retention). Successful treatment of the therapy is defined as 
a 50% improvement in symptoms. Kessler et al38 reported 
that the use of the tined electrode was less prone to migration 
and allowed for longer testing periods resulting in higher 
success rates of the PNE test. The investigators advised a 
testing period of 14 days. If the PNE is evaluated as effective 
and a wire electrode was used for the procedure, it will be 
replaced with a tined electrode (e.g., tined lead). The wire 
of the electrode is tunneled under the skin and connected to 
a surgically implanted internal pulse generator that contains 
the battery and works similar to a pacemaker.39 This latter 
device can be magnetically activated and accessed via a 
remote control for periodical read outs of the machine and 
to change settings when needed.
SNS has proven efficacy in iOAB, neurogenic blad-
der disease, hypocontractility of the bladder and fecal 
 incontinence.40–42 It is currently being evaluated in patients 
with chronic pelvic pain syndrome and chronic constipation. 
The advantages of this device are that it applies continuous 
stimulation to improve lower urinary tract control and that 
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the device is internally located. Battery life is on average 
5–7 years but depends on 1) the system (there is a large bat-
tery and a small battery system) and 2) how energy efficient 
the internal device settings are (pulse intensity and fre-
quency31). The internal InterStim stimulator (the pacemaker) 
does have to be surgically replaced when the pacemaker 
battery is empty, but the tined electrode can be left in place. 
van Voskuilen et al31 investigated long-term results of SNS in 
149 patients in a single-center study with a mean follow-up 
of 63 months. This study reported a considerable rate of 129 
reoperations and 21 explanted of the stimulators. Infection 
problems occurred in only six patients, resulting in surgical 
removal of one device. van Kerrebroeck et al undertook a 
large multicenter study in 152 patients with refractory OAB 
(n=121) or urinary retention (n=31). They reported 36 device-
related technical failures requiring surgery in 60 patients. 
These 60 patients underwent an additional 110 surgeries 
during a 5-year time span.40 Nonetheless, 70% of the patients 
experienced therapeutic benefit from the treatment after 
5 years, and this was in a group that was refractory to other 
therapies. Treatment failure occurred mostly within the first 
6–24 months after placement. For refractory OAB, long-term 
efficacy was shown with incontinence episodes reducing 
58% and the number of voids per day 40%.40 Siegel et al43 
performed a prospective multicenter in 272 OAB patients 
(90% female) who received SNS therapy for an average of 
3 years. This study showed similar or even better success rates 
compared to the van Voskuilen and van Kerrebroeck studies. 
This study also reported a very consistent improvement in 
quality of life with 52% of patient reporting that interference 
of urinary symptoms on everyday life was greatly reduced 
and a significant improvement was seen on coping, social, 
sleeping and health-related quality-of-life subscales.43 van 
Kerrebroeck et al40 also evaluated SNS efficacy in 31 patients 
Figure 4 Sacral nerve stimulation with InterStim device and pelvic anatomy for dorsal genital nerve (DGN) stimulation and percuteneous tibial nerve stimulation.
Notes: (A) A schematic diagram of how sacral nerve stimulation (SNS) works with a tined lead electrode that is placed through sacral foramen S3. The nerve fibers from 
the posterior tibial nerve are part of the large sciatic nerve that descends from the pelvic region toward the lower extremities. Also the pudendal nerve is shown, which 
contains the nerve fibers from the DGN, which branches from this nerve and can be used for electrical DGN stimulation. (B) An X-ray of the pelvic region from a patient 
with an InterStim SNS device with the green arrow pointing at the tined lead. The pulse generator is seen in the upper right corner of the image. (C) An image of an SNS 
device that was explanted. This was the first SNS device that was implanted in Europe in 1989.
Abbreviations: DGN, dorsal genital nerve; SNS, sacral nerve stimulation.
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with urinary retention. SNS therapy was considered success-
ful in 71% of the patients, and voided volumes increased 
considerably in this group, which was shown by an average 
reduction of catherizations/day from 5.3 to 1.9 and a decrease 
of catherized volumes from 380 mL to 109 mL.
Percutaneous posterior tibial nerve 
stimulation (P-PTNS)
P-PTNS is a low invasive neuromodulation technique that 
intermittently stimulates the easily accessible PTN at the 
ankle with a transcutaneously placed needle electrode44,45 
(Figure 1). Electrical stimulation of the PTN for bladder 
dysfunction was first attempted by McGuire et al46 and the 
percutaneous technique was developed by Stoller. P-PTNS 
resembles traditional acupuncture techniques but combines it 
with electrical pulse stimulation. Like stated before, P-PTNS 
indirectly intervenes in the neural pathways of the lower 
urinary tract and most likely modulates higher spinal and/or 
brain reflexes to treat OAB symptoms.24,47,48 P-PTNS is also 
experimentally investigated for other indications such as 
urinary retention, pelvic pain, pediatric bladder dysfunction, 
fecal incontinence and anal fissures.49 The therapy comprises 
weekly clinical visits for 30–60 min stimulation sessions for 
up to 12 weeks. Pulse intensity and frequency can be adjusted 
to achieve optimal response in each individual patient. After 
this initial 12-week period, monthly visits are recommended 
to maintain the desired treatment effect.
The full mechanism of action of P-PTNS is still not 
fully understood, and the therapy was initially received with 
skepticism by physicians. This was until Finazzy-Agr et 
al50 and Peters et al21,51,52 demonstrated true efficacy in two 
randomized, placebo-controlled trials. The therapy is cur-
rently included in the guidelines for OAB treatments from 
the International Continence Society, American Urological 
Association, and European Association of Urology.10
The SUmiT trial investigated P-PTNS treatment in 
220 patients with OAB in a double-blind, sham-controlled 
randomized trial.21 Of the treatment group, 54% reported 
moderate to severe improvement in symptoms, compared to 
20% in the sham group.21 Although there was a large placebo 
effect, the treatment arm reported a significant reduction 
in moderate to severe urgency episodes from 8.3 to 3.7, 
which was significantly better compared to the sham-treated 
group (8.0–5.0). Similar improvements were reported in 
incontinence episodes per day with a significant reduction 
in the treatment arm (3.0–0.3) compared to the sham-treated 
group (1.8–1.0). For initial responders, the overall long-term 
efficacy was good with a reported 96% sustained effect after 
1 year.53 Regarding safety, Peters et al21 reported that the 
needle insertion and electrical stimulation could create mild 
local discomfort, but adverse events from P-PTNS therapy 
such as local bruising, bleeding and discomfort all occurred 
in <1% of patients.
Wireless internal tibial nerve stimulation
This technique is based on the same principles as P-PTNS 
in combination with the wireless electrical pulse generation 
technique that is used in the SARS Finetech–Brindley System. 
The stimulation of the PTN is achieved with a small, surgi-
cally implantable electrical pulse transmitter with electrodes 
that are attached near the PTN at the ankle (Figure 1). There 
is a battery-free transmitter that converts the power and con-
trol signals from an extracorporeal controller into electrical 
pulses that are guided through the stimulation electrodes. 
This extracorporeal controller is placed on the skin near the 
receiver, and radio frequency transmission is used to transfer 
energy to the receiver. The controller settings can be adjusted 
for altering pulse frequency and intensity, and the system can 
be independently operated by patients for on demand PTN 
stimulation. The Urgent-SQᵀᴹ (Cogentix Medical, former 
company Uroplasty, Minnetonka, MN, USA) was the first 
implant that was developed, and it was evaluated in eight 
patients with refractory OAB and a positive response on 
P-PTNS treatment in 2003.54 This device was developed for 
ambulant use to reduce the burden and costs of the mandatory 
clinical visits that are part of the conventional P-PTNS therapy. 
Furthermore, the added freedom of on-demand stimulation 
could improve the overall efficacy of PTN stimulation. Initial 
results of this pilot were promising, with a 50% improve-
ment in symptoms in half of the patients after 1 year. In one 
patient, the implant was removed within the first year due to 
technical failure and one patient had discomfort at the site of 
the implant. A 9-year follow-up study was conducted in this 
patient cohort.55 The results showed that one patient lost the 
usual sensory and motor responses during stimulation after 
4 years. It was concluded that this was a probable technical 
failure. Of the six remaining patients, three were still using 
the device on a regular basis with consistently improvement 
in quality of life compared to baseline. These three patients 
would also recommend the therapy to others. The device was 
never clinically introduced on a large scale. However, since 
the arrival of more scientific evidence that supports P-PTNS 
therapy, interest for these ankle implants has gained. A clinical 
trial was recently initiated to evaluate a new device called the 
BlueWind Medical Renovaᵀᴹ (BlueWind Medical Ltd, Her-
zliya, Israel) (Figure 1). This device uses the same principles 
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and technology, but it is much smaller than the Urgent-SQᵀᴹ 
and has no wire electrodes (Figure 1).
Percutaneous DGN stimulation
DGN stimulation with needle electrodes is an experimental 
neuromodulation technique to treat neurogenic and OAB 
disease, and it is not applied in routine clinical practice.56 
Like mentioned before, the DGN is a branch of the pudendal 
nerve57 (Figures 1 and 4). Stimulating the DGN may have 
several advantages compared to other frequently stimulated 
nerves such as the sacral nerves and the PTN. For instance, 
the DGN is, such as the PTN, easily accessible with a small 
percutaneously inserted needle electrode but can also be 
accessed with a wire electrode that is guided through a hollow 
needle.56 The nerve is also a direct branch of the pudendal 
nerve and has therefore, in theory, a shorter access to the 
nerves that control lower urinary tract function compared to 
the PTN. Successful stimulation of the DGN can be detected 
by monitoring the presence of the genitoanal reflex.56 Martens 
et al56 experimented with percutaneous DGN stimulation in 
six SCI patients with DO and demonstrated with urodynamics 
that DO can be inhibited with this technique. Goldman et al58 
investigated DGN stimulation in 21 female OAB-wet patients 
with a percutaneous wire electrode. Patients received 7 days 
of continuous stimulation, and all but two completed the 
study (n=19). In 47% of the patients, there was a reduction in 
incontinence episodes/day of >50%, and 81% of patients had 
a reduction of severe urgency episodes/day of over 50%. The 
results of a pilot study by van Breda et al also show promise.59 
This study investigated on demand DGN stimulation through 
a percutaneously placed wire electrode in six patients with 
non-neurogenic OAB. Patient reported 73% improvement in 
symptoms, including urgency an incontinence severity. Larger 
study cohorts are needed to determine the applicability of per-
cutaneous DGN stimulation. Transcutaneous electrical nerve 
stimulation (TENS) of the DGN has also been investigated 
(refer the “TENS” section).
Pudendal nerve stimulation
To target the pudendal nerve more specifically, Spinelli et 
al60 described a surgical procedure that places an electronic 
lead into Alcock’s canal via either a perineal approach or a 
posterior approach. The technique uses the same InterStim 
device with a tined lead for continuous nerve stimulation as 
in SNS. The hypothesis was that targeting the pudendal nerve 
alone would potentially help neurogenic bladder patients in 
which SNS did not work sufficiently.61 Spinelli et al per-
formed a pilot study in 15 patients with neurogenic bladder 
disease and reported encouraging results with a decrease in 
incontinence episodes/day from 7 to 2.6. This coincided with 
a twofold increase in bladder capacity and a positive effect 
on constipation meaning that stool evacuation improved from 
2.6 to 7 times/wk.
Groen et al62 investigated the applicability of a mini 
neurostimulator called the Bion that was placed near the 
pubendal nerve in Alcock’s canal. This pilot study of six 
patients was successful in significantly decreasing the degree 
of incontinence, with no severe adverse event. Surgical access 
and vascular control in women but especially in men was con-
sidered challenging. Despite the positive clinical outcomes, 
no follow-up study of this device has been done. Peters et 
al63 investigated whether isolated pudendal nerve stimulation 
was superior to SNS with a cross-over study in 30 patients. 
Results were remarkably in favor for pudendal nerve stimula-
tion and were chosen as the superior lead in 79.2% with an 
average reduction of symptoms of 63% compared to 46% 
for the SNS group. A total of 80% of the patients who were 
evaluated had a positive response and received a permanent 
implant for pudendal nerve stimulation with only minimal 
complications reported. Wang et al performed intermittent 
electrical pudendal nerve stimulation with long percutane-
ously placed needle electrodes. This group performed a long-
term efficacy study of at least 60 months in 106 patients with 
urgency–frequency who received on average 21.6 stimulation 
sessions.64 The study reported an 85% of patients who had an 
improvement in symptoms of over 50%. In general, puden-
dal nerve stimulation is still not a routinely applied therapy. 
Especially the study results by Spinelli et al60 and Peters et 
al63 in 2005 seem promising, but more evidence from larger 
study cohorts with long-term follow-up is needed to prove 
clinical superiority of pudendal nerve stimulation over SNS.
TENS
The TENS technique was developed in the 1970s to relieve 
pain. Dermal patch electrodes are used to transcutaneously 
stimulate internal nerves. Sudin introduced this technique 
in urological patients in 1974, and it is currently applied 
for patients with iOAB, neurogenic OAB and pelvic pain 
syndrome. The technique can be applied in different regions 
to target different nerves that are involved in lower urinary 
tract control and can be used for continuous or on-demand 
stimulation.
The anatomical areas where TENS is applied include 
1) the sacral area to stimulate sacral and pudendal nerves, 
2) the ankle to stimulate the PTN and 3) the genital/groin 
area to stimulate the DGN and/or pudendal nerve. The real 
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 advantages of this technique are 1) the use of dermal patch 
electrodes that are noninvasive and 2) the possibility for 
patients to learn and apply the technique themselves. Fjorback 
et al65 reported that on-demand stimulation of sacral nerves 
with TENS in neurogenic bladder patients with multiple scle-
rosis achieved some inhibition of DO, but authors concluded 
this worked insufficiently for clinical use. A large systematic 
review was performed to evaluate the efficacy of TENS for 
neurogenic bladder disease.66 This study included 22 studies 
with a total of 450 patients. Conclusions of this systematic 
review were for a large degree based on the results from a 
randomized controlled trial by Guo et al who investigated 
sacral stimulation in 61 poststroke patients with incontinence. 
This study showed a significant improvement in incontinence 
episodes per day from 4.0 to 1.6 in the treatment group 
compared to 4.2 to 3.86 in the control group.67 The authors 
of the systematic review reported that many of the included 
studies were of poor quality, but they did conclude that TENS 
appeared to be effective at reducing symptoms and that the 
technique appeared safe.66
DGN stimulation with TENS was investigated in a small 
group (n=7) of patients with neurogenic DO by van Breda 
et al.59 The study reported that DGN stimulation with TENS 
increased bladder capacity and voided volumes.59 A urody-
namic study also reported that DGN stimulation with dermal 
patch electrodes can inhibit DO in neurogenic patients.68 
Nonetheless, larger studies are needed to demonstrate whether 
DGN stimulation with TENS has an real effect on OAB.69
The overall clinical evidence for the use of PTNS and SNS 
for treating OAB is more convincing compared to TENS. The 
skin is a large barrier to overcome for electrical stimulation, 
which is a clear downside of the TENS technique. Nonethe-
less, the use of dermal patch electrodes does give practical 
advantages over PTNS and SNS. Because TENS is nonin-
vasive, it is potentially more suitable for pediatric patients, 
although this is still considered experimental. Because of the 
advantages that TENS has over other therapies, it has obtained 
a niche in clinical practice for bladder dysfunction treatment.
Magnetic nerve stimulation
Magnetic nerve stimulation is an extracorporeal noninvasive 
technique that can transmit electrical currents to activate 
nerves in deeper tissue layers. It is a painless technique, but 
this type of stimulation can cause discomfort. The technique 
itself was developed in Sheffield and uses magnetic fields to 
generate electrical currents in the body.70 In daily practice, it 
is sporadically used for pelvic floor muscle training in women 
with stress urinary incontinence (SUI). Fujishiro et al71 
performed a sham-controlled trial evaluating the efficacy of 
magnetic nerve stimulation of the pelvic area in 62 patients 
with SUI. Only a single 30-min stimulation session with a 
magnetic coil was performed in this study. The follow-up was 
for 1 week. The study reported a reduction in total amount 
of incontinence episodes in 3 days from 4.3 to 2.2 in the 
treatment group (n=31), which was significantly more than 
the sham-treated group (3.9 to 3.2; n=31). Recently, some 
trials have been conducted in patients with OAB. Lo et al72 
investigated magnetic nerve stimulation in 49 patients with 
SUI and 44 patients with OAB in a retrospective study. A 
electromagnetic chair was used for stimulation two times per 
week for 9 consecutive weeks. In all, 21 patients discontin-
ued treatment. The results from the patients who completed 
the treatment showed that 48% of the OAB patients were 
symptom free (no urgency, frequency or incontinence) after 
treatment and 33% of SUI patients were symptom free (no 
incontinence). Although these are promising results, we do 
not know how long the effects last, and the results should be 
investigated in a larger study cohort. The technique is also not 
very specific in targeting individual nerves. Magnetic nerve 
stimulation is currently not widely used in clinical practice, 
and further research is mandatory to determine true clinical 
(long term) efficacy.
Summary
For decades, neurostimulation and neuromodulation thera-
pies have been a validated and widely used treatment option 
for lower urinary tract dysfunction. The neurostimulation 
techniques that are currently available vary from very low 
invasive treatments to more high invasive therapies that 
require elaborate surgery. Some experimental techniques 
look promising but lack follow-up studies in larger cohorts to 
determine efficacy. This is important because placebo effects 
are often considerable in studies that investigate bladder 
dysfunction treatments.
Devices are improving from a technical point of view 
and are becoming more refined. But there is still room for 
improvement. Internal stimulator devices are foreign bodies 
and are therefore at risk of infection. In a wet and dynamic 
environment, technical failure can occur. The future directive 
for this field is to fine tune these devices. For stimulators, 
there is improvement in battery life and finding ways for 
external recharging of batteries to avoid resurgery. Improv-
ing the size and robustness of the apparatus and electrodes 
and making the surgical placement easier are factors that 
could improve efficacy, durability and tolerability of these 
therapies. For the intermittent neuromodulation therapies 
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such as PTNS, techniques should be focused on improving 
the independence of the patient with more home-based and 
ambulant therapies. The potential wireless internal tibial 
nerve stimulation technique is a good example for this.
Neuromodulation has a proven efficacy in refractive OAB 
patients who do not respond to pharmacological therapies. It 
has improved the quality of life of many patients who suffer 
from lower urinary tract dysfunction and urinary incontinence. 
Neurostimulation therapies such as SARS helped to dramati-
cally increase independence for wheelchair bound spinal cord 
patients. Indications for different types of neuromodulation 
therapies are broadening since new studies reveal efficacy of 
these therapies in other conditions such as pelvic pain. Neuro-
stimulation in urology has been a pioneering field and is an 
example of how novel engineering techniques can be picked up 
and designed into clinically effective therapies that are nowa-
days mainstay therapies for lower urinary tract dysfunction.
Written informed consent for X-ray images from patients 
was deemed not required by the Radboud University Nijme-
gen Medical Center for this study because patient data were 
de-identified from these X-ray images.
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